Drug Trial Radar · NCT04734262
A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)
Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
98
Actual
Start
Apr 1, 2021
Primary completion
Jun 1, 2026
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Fudan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 2, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy and safety of sitravatinib plus tislelizumab or combination with nab-paclitaxel in locally recurrent or metastatic triple-negative breast cancer (TNBC) patients.
Conditions
- Metastatic Breast Cancer
Interventions
SitravatinibDrug
Sitravatinib QD PO Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases
TislelizumabDrug
Tislelizumab Q3W IV Tislelizumab is a programmed death receptor-1 (PD-1) blocking antibody
Nab-paclitaxelDrug
Nab-paclitaxel D1, D8 Q3W IV Nab-paclitaxel is a chemotherapy drug which combines the chemotherapy drug paclitaxel with albumin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR) by Investigator in Cohort A, Cohort B and Cohort CTime frame: Up to 12 months
- Number of participants experiencing ≥ Grade 3 TRAEs in Cohort BTime frame: Up to 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.